Rspo1 binding agents and uses thereof
AssigneeOncoMed Pharmaceuticals, Inc.
InventorAustin L. GURNEY
Life of this patent
Estimating the term…
Abstract
The present invention relates to RSPO-binding agents, particularly antibodies that specifically bind human RSPO1. Also described are methods of treating cancer and other diseases, comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient in need thereof.
Claims65
An isolated antibody that specifically binds human R-spondin 1 (RSPO1), which comprises a heavy chain variable region comprising SEQ ID NO:32 and a light chain variable region comprising SEQ ID NO:33.
An isolated antibody that specifically binds human R-spondin 1 (RSPO1), which comprises a heavy chain variable region having at least 90% sequence identity to SEQ ID NO:32 and a light chain variable region having at least 90% sequence identity to SEQ ID NO:33, wherein the antibody comprises a heavy chain CDR1 comprising TGYTMH (SEQ ID NO:6), a heavy chain CDR2 comprising GINPNNGGTTYNQNFKG (SEQ ID NO:7), and a heavy chain CDR3 comprising KEFSDGYYFFAY (SEQ ID NO:8), a light chain CDR1 comprising KASQDVIFAVA (SEQ ID NO:9), a light chain CDR2 comprising WASTRHT (SEQ ID NO:10), and a light chain CDR3 comprising QQHYSTPW (SEQ ID NO:11).
An isolated antibody that specifically binds human RSPO1, which comprises a heavy chain comprising SEQ ID NO:35 and a light chain comprising SEQ ID NO:37.
An isolated antibody that specifically binds human R-spondin 1 (RSPO1), which comprises a heavy chain having at least 90% sequence identity to SEQ ID NO:35 and a light chain having at least 90% sequence identity to SEQ ID NO:37, wherein the antibody comprises a heavy chain CDR1 comprising TGYTMH (SEQ ID NO:6), a heavy chain CDR2 comprising GINPNNGGTTYNQNFKG (SEQ ID NO:7), and a heavy chain CDR3 comprising KEFSDGYYFFAY (SEQ ID NO:8), a light chain CDR1 comprising KASQDVIFAVA (SEQ ID NO:9), a light chain CDR2 comprising WASTRHT (SEQ ID NO:10), and a light chain CDR3 comprising QQHYSTPW (SEQ ID NO:11).
An antibody comprising the heavy chain variable region encoded by the plasmid deposited with ATCC as PTA-121494.
An antibody comprising the heavy chain encoded by the plasmid deposited with ATCC as PTA-121494.
An antibody comprising the light chain variable region encoded by the plasmid deposited with ATCC as PTA-121495.
An antibody comprising the light chain encoded by the plasmid deposited with ATCC as PTA-121495.
An antibody comprising the heavy chain variable region encoded by the plasmid deposited with ATCC as PTA-121494 and the light chain variable region encoded by the plasmid deposited with ATCC as PTA-121495.
An antibody comprising the heavy chain encoded by the plasmid deposited with ATCC as PTA-121494 and the light chain encoded by the plasmid deposited with ATCC as PTA-121495.
A polypeptide comprising a sequence selected from the group consisting of:
- SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, and SEQ ID NO:37.
An isolated polynucleotide molecule comprising a nucleotide sequence selected from the group consisting of:
- SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, and SEQ ID NO:41.
A plasmid deposited with ATCC and assigned designation number PTA-121494.
A plasmid deposited with ATCC and assigned designation number PTA-121495.
Dependencies are inferred from the claim text.